RetinalGenix Technologies
RetinalGenix Technologies is a pre-revenue R&D-stage medical device company developing retinal imaging combined with pharmacogenetic mapping for early detection of ocular and systemic diseases, including diabetic retinopathy, AMD, and Alzheimer's.
- Company typePublic
- Founded2017
- HeadquartersApollo Beach, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What RetinalGenix Technologies does
RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic medical device and therapeutics company developing an integrated platform that pairs high-resolution, non-dilating retinal imaging with a proprietary DNA/RNA/GPS pharmacogenetic mapping capability for the early detection of ocular and systemic diseases. The product portfolio comprises the RetinalCam home/remote patient-activated monitoring device, a portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and two early-stage therapeutic candidates—RTG-2023 for dry AMD (currently in a clinical study) and RTG-2024 for Alzheimer's dementia. Core foundational IP is held under an exclusive worldwide sublicense from Sanovas Ophthalmology LLC, and the company operates through wholly-owned subsidiary DNA/GPS Inc., acquired in 2022.
RetinalGenix Technologies firmographics
Firmographics- Name
- RetinalGenix Technologies
- Legal name
- RetinalGenix Technologies Inc.
- Website
- https://retinalgenix.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RetinalGenix Technologies is a pre-revenue R&D-stage medical device company developing retinal imaging combined with pharmacogenetic mapping for early detection of ocular and systemic diseases, including diabetic retinopathy, AMD, and Alzheimer's.
- Ownership category
- akta.pro rank
RetinalGenix Technologies industry classification
Industry- Product category
- Ophthalmic medical devices and diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)Ophthalmology Gene TherapiesOphthalmology Pharmaceuticals
Keywords
Where RetinalGenix Technologies is headquartered
LocationHeadquarters
- HQ city
- Apollo Beach
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
RetinalGenix Technologies business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Genetic Testing Kits Sales: Sale of DNA/GPS oral swab laboratory test kits to patients through clinician offices, direct-to-consumers, and distributors. Planned launch late 2026. Third-party genetic testing company handles manufacturing, distribution, clinical processing and reporting.
- Retinal Imaging Platform: Revenue from RetinalCam remote monitoring device and RetinalGeniX imaging system. RetinalCam planned for launch end of 2026. FDA clearance not required for RetinalCam as non-diagnostic screening tool.
- Therapeutic Drug Development: Development of pharmaceutical products RTG-2023 for dry AMD and RTG-2024 for Alzheimer's syndrome dementia. Drug candidate RTG-2023 in clinical study phase. Revenue potential through drug commercialization pending regulatory approval.
- Patient Database Services: Secure, interoperable database system combining genetic and imaging data. Anonymized database for research purposes creating future IP opportunities. Patient-controlled access with HIPAA protections.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Genetic testing kits - pricing not publicly disclosed |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
RetinalGenix Technologies product offering
Product offeringCore offering
RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic company developing an integrated platform of medical devices, genetic testing, AI software, and therapeutic drug candidates. Its core offerings include the DNA/RNA/GPS Pharmaco-Genetic Mapping platform, the RetinalCam home/remote retinal monitoring device, the portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and therapeutic drug candidates RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's/dementia). The platform is designed for early, non-invasive, dilation-free detection of ocular and systemic diseases including AMD, diabetic retinopathy, glaucoma, Alzheimer's, Parkinson's, and cardiovascular conditions.
Product overview
RetinalGenix Technologies operates as an integrated four-pillar platform combining: (1) DNA/RNA/GPS Pharmaco-Genetic Mapping for genetic testing and biomarker discovery, (2) Retinal Imaging devices including the portable Retinal Imaging Screening Device and RetinalCam for home/remote monitoring, (3) the RECAD AI System for secure patient-controlled database combining genetic and imaging data, and (4) Therapeutic development including RTG-2023 for dry AMD and RTG-2024 for Alzheimer's dementia. The platform enables early disease detection through non-invasive retinal imaging and genetic profiling for ocular, neurodegenerative, cardiovascular, vascular, and metabolic conditions.
Differentiator
Problem solved
Functional benefit
Brands
- DNA/RNA/GPS™: Proprietary pharmacogenetic mapping platform for screening, monitoring, and creating diagnostic markers for systemic and retinal disorders
- RetinalCam™
- RECAD™ AI System
- RetinalGeniX™
- RetinalGenix RetinalCam
Products and services
- RetinalCam In-home/remote, patient-activated retinal monitoring and imaging device that provides 24/7 real-time communication and physician alerts, designed for patient self-monitoring without pupil dilation. Targeted for deployment through pharmacies, clinics, hospitals, nursing homes, urgent care centers, walk-in clinics, doctors' offices, optical outlets, and home use.
- Retinal Imaging Screening Device Portable, high-resolution retinal imaging system providing a wide field of view without requiring pupil dilation, designed for cost-effective mass screening of ocular, neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
- DNA/RNA/GPS Pharmaco-Genetic Mapping Platform Proprietary pharmacogenetic mapping platform that screens, monitors, and generates data for profiling, trend identification, and diagnostic markers for systemic and retinal disorders using DNA and RNA biomarkers; supports drug repositioning and validation.
- RECAD AI System (RetinalGenix Eye Care Anonymized AI Database)
- RTG-2023 Therapeutic drug candidate in development for the treatment of dry age-related macular degeneration (dry AMD), intended to prevent progression from dry to wet AMD. Currently in clinical study phase with 490 patients enrolled.
- RTG-2024 Therapeutic drug candidate in development for the treatment of Alzheimer's syndrome dementia, with a provisional patent submitted in November 2023 targeting the root causes of disease at the molecular and cellular level.
- DNA/GPS Oral Swab Genetic Test Kit Home-use oral swab genetic test kit sold through clinician offices, direct-to-consumer channels, and distributors, designed to enable personalized genetic profiling tied to the DNA/RNA/GPS Pharmaco-Genetic Mapping platform.
Quantifiable outcome
- 200 million people worldwide with AMD projected to reach 300 million by 2040
- +4 more outcomes
Companies that use RetinalGenix Technologies
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
RetinalGenix Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
RetinalGenix Technologies partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Seer, Inc.coreCollaboration to develop early detection biomarkers for diseases using retinal imaging and proteomic profiling. Aims to improve diagnosis and monitoring of neurodegenerative, systemic, and retinal diseases including Alzheimer's and Parkinson's by integrating RetinalGenix's non-invasive retinal imaging platform with Seer Bio's proteomic profiling technology.
- RGEN Inc. (RGEN Clinical Genotyping Laboratory)coreStrategic partnership to combine retinal imaging technology with clinical-grade DNA genotyping for early detection of neurodegenerative, systemic, and retinal diseases including AMD, glaucoma, diabetic retinopathy, Alzheimer's, and Parkinson's. Plans for commercial deployment in primary care offices, clinics, and ophthalmology settings, along with healthcare payer partnerships for preventative care coverage.
- MBC BioLabscoreLaboratory lease agreement with MBC BioLabs in San Carlos, California. Company will use the facility to develop its DNA/RNA/GPS Pharmaco-Genetic Mapping platform and repurpose drugs for dementia, parkinsonism, and macular degeneration. Option for Mission BioCapital to invest.
- Pearl IRBcoreInstitutional Review Board engaged to conduct study for personalizing medical evaluations for patients receiving intraocular injections for wet macular degeneration. Study aims to determine genetic basis for treatment success/failure and help patients evaluate treatment necessity. Enrolling up to 100 patients in 2026 with expansion to multistate physicians planned for winter 2026.
- Seven Springs Surgery CenterminorEngaged phlebotomists from Seven Springs Surgery Center to facilitate blood draw process necessary for the Pearl IRB study.
- Avania ClinicalcoreContracted as initial advisor for therapeutic drug development, specifically for RTG-2023 and RTG-2024 product candidates.
- ADM Tronics Unlimited, Inc.coreAmended and Restated Master Services Agreement for software design, engineering, and regulatory services related to RetinalCam and RetinalGeniX. Agreement renewed in 2025 to support ongoing new camera system development.
- Sanovas Ophthalmology LLCcoreSublicense agreement granting exclusive worldwide license to intellectual property including six patents, two patent applications, and two trademark applications relating to eye and ocular visualization and monitoring. Royalty of mid-single digit percentage of Net Sales. CEO Jerry Katzman is managing member of Sanovas.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
RetinalGenix Technologies competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
RetinalGenix Technologies social profiles
Digital presenceRetinalGenix Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
RetinalGenix Technologies leadership team
Management profileNumber of profiles
Profiles2 records
RetinalGenix Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
RetinalGenix Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RetinalGenix Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RetinalGenix Technologies
What does RetinalGenix Technologies do?
RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic company developing an integrated platform of medical devices, genetic testing, AI software, and therapeutic drug candidates. Its core offerings include the DNA/RNA/GPS Pharmaco-Genetic Mapping platform, the RetinalCam home/remote retinal monitoring device, the portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and therapeutic drug candidates RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's/dementia). The platform is designed for early, non-invasive, dilation-free detection of ocular and systemic diseases including AMD, diabetic retinopathy, glaucoma, Alzheimer's, Parkinson's, and cardiovascular conditions.
Is RetinalGenix Technologies a public or private company?
RetinalGenix Technologies is a public company. It is classified as public and is currently operating.
When was RetinalGenix Technologies founded?
RetinalGenix Technologies was founded in 2017. It employs 1 to 10 people.
Where is RetinalGenix Technologies based?
RetinalGenix Technologies is headquartered in Apollo Beach, United States, in the North America region.
How does RetinalGenix Technologies make money?
Four revenue lines are on record. Genetic Testing Kits Sales are the primary driver. The others are retinal Imaging Platform, therapeutic Drug Development and patient Database Services.
Does RetinalGenix Technologies have an API?
No public API is recorded for RetinalGenix Technologies.
What industry is RetinalGenix Technologies in?
RetinalGenix Technologies's product category is Ophthalmic medical devices and diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 334510 and its SIC code is 3841.